Actio has built an integrated drug discovery engine that leverages deep expertise in human genetics and bioinformatics to identify shared biology between rare and common diseases. Through the development of precision medicines for homogenous rare patient populations, Actio builds on a foundation of data to rationally target large, heterogeneous patient populations.
Actio is developing a pipeline of new medicines with the goal to enhance the probability of clinical success and deliver better medicines for all patients. Founded in October 2021 and built on the experience of Drs. David Goldstein and John McHutchison, Actio is funded by EcoR1, Droia, and Deerfield Management.